Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
The FDA feedback on the end-of-phase-2 meeting with the regulator's expectations and guidance for the ABX464 phase 3 study design in ulcerative colitis is a very important step for Abivax. Prof. Hartmut J. Ehrlich, M.D.
- End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)